Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…

Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…

In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…

At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF receptor antagonist Ianalumab with Eltrombopag in patients with primary immune thrombocytopenia (ITP). The results signal a potential paradigm shift for patients who have failed first-line corticosteroid therapy, offering a new avenue for durable disease control.

At the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. Lucy Fox from the Peter MacCallum Cancer Centre (Australia) presented the highly anticipated results of the IBMDX study. This landmark trial evaluated the clinical utility and economic impact of "Upfront Whole Genome Sequencing (WGS)" in patients with suspected Inherited Bone Marrow Failure Syndromes (IBMFS). The findings suggest a paradigm shift is underway: WGS not only achieves a diagnostic yield of 37%—surpassing traditional panels and exome sequencing—but also uncovers complex genomic mechanisms previously invisible to standard testing.

At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab ("Tech-Dara") against standard-of-care regimens (Dara-Pd or Dara-Vd) in patients with relapsed/refractory multiple myeloma (RRMM), the study delivered historic results. The Tech-Dara combination achieved a Hazard Ratio (HR) for progression-free survival of 0.17—the most profound efficacy signal reported to date for BCMA-targeted therapies—signaling a potential "functional cure" for patients with early relapse.

At the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Sklodowska-Curie National Research Institute of Oncology (Poland) presented the highly anticipated results of a global Phase III clinical trial. This study is the first head-to-head comparison evaluating the efficacy and safety of the non-covalent BTK inhibitor, pirtobrutinib, against the standard immunochemotherapy regimen of bendamustine plus rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

At the 67th American Society of Hematology (ASH) Annual Meeting in 2025, a groundbreaking Late-Breaking Abstract (LBA) presented by Professor Phoebe Joy Ho (Royal Prince Alfred Hospital, Australia) signaled a potential paradigm shift in the treatment of multiple myeloma. The preliminary results from the Phase 1 inMMyCAR study of KLN-1010—the first in vivo anti-BCMA CAR-T therapy—demonstrated that deep molecular responses can be achieved without the complex logistics of ex vivo manufacturing or the toxicities associated with lymphodepleting chemotherapy.